Research and development commitments in an integrated plasma collection and plasma fractionation environment.
Plasma fractionation has emerged as one of the most scientifically demanding fields in the biopharmaceutical area. Producing safe plasma derivatives implies the development, use, and proper understanding of sensitive testing technologies to detect infection markers in starting plasma. It also requires the implementation of carefully selected, nondenaturing, efficient plasma protein purification and viral reduction technologies that do not alter the physiological functions and clinical potential of plasma proteins. Success in this field can be achieved only by a strong commitment to sustain constant research and development of projects targeting the production of safer and innovative plasma products.
Radosevich
M
M
Haemonetics Plasma Product Services, Lille, France.
D001779:Blood Coagulation Factors / Q000302:isolation & purification / Q000592:standards; D001798:Blood Proteins / Q000302:isolation & purification* / Q000592:standards; D005591:Chemical Fractionation; D004345:Drug Industry / Q000458:organization & administration*; D005544:Forecasting; D006040:Goals; D016756:Immunoglobulins, Intravenous / Q000302:isolation & purification / Q000592:standards; D017053:Infection Control / Q000458:organization & administration; D010949:Plasma / Q000737:chemistry*; D012106:Research / Q000458:organization & administration*; D012449:Safety; D012680:Sensitivity and Specificity; D014766:Viremia / Q000821:virology; D014780:Viruses / Q000187:drug effects / Q000302:isolation & purification
D001779:Blood Coagulation Factors; D001798:Blood Proteins; D016756:Immunoglobulins, Intravenous